About us - PM Group
BioPhorum’s latest Technology Strategy explores “How to develop a control strategy for continuous bioprocesses”.
Cost-effective, rapid, and flexible biopharmaceutical production is an industry-wide challenge. Process intensification through continuous manufacturing has proved successful in other industries and is a promising area of investigation for researchers, vendors, and biomanufacturers.
The Technology Strategy examines the simplification of linkages between unit operations in collaboration with Asahi Kasei, CRB, Emerson, Exyte, FUJIFILM Diosynth Biotechnologies, GSK, Janssen Inc., Lonza, Cytiva, Rockwell Automation, Siemens, Thermo Fisher Scientific, Merck Group, Novo Nordisk, PM Group Sartorious Stedim and Schneider Electric
Facilitated by Graeme Moody